Abstract Purpose of Review The therapeutic landscape for non-melanoma skin cancer
(NMSC) has recently expanded with the development of effective and targeted …

Background Cancer surgery is necessary and life-saving. However, the majority of patients
develop postoperative recurrence and metastasis, which are the main causes of cancer …

Despite the success of checkpoint blockade in some cancer patients, there is an unmet need
to improve outcomes. Targeting alternative pathways, such as costimulatory molecules (eg …

Abstract PD-1/PD-L1 checkpoint therapy for cancer is commonly considered to act by
reactivating T cells in the tumor microenvironment. Here, we present data from 2 mouse …

Novel neoadjuvant therapy regimens are warranted for oral squamous cell carcinoma
(OSCC). In this phase I trial (NCT04393506), 20 patients with locally advanced resectable …

As a potent lymphocyte activator, interleukin-2 (IL-2) is an FDA-approved treatment for
multiple metastatic cancers. However, its clinical use is limited by short half-life, low potency …

Treatment of advanced (metastatic) non-small-cell lung cancer (NSCLC) is currently mainly
based on immunotherapy with antibodies against PD-1 or PD-L1, alone, or in combination …

Simple Summary Human epidermal growth factor receptor 2 (HER2) positive breast cancer
is a heterogeneous disease. Among different therapeutic approaches, immunotherapies …

Adjuvant immunotherapies targeting CTLA4 or PD-1 recently demonstrated efficacy in the
treatment of earlier stages of human cancer. We previously demonstrated using mouse …

Simple Summary Hepatocellular carcinoma (HCC) is the most common type of liver cancer,
accounting for approximately 85–90% of all cases of liver cancer worldwide. The five-year …